Bayston Multicenter Antimicrobial PD Catheter Safety Study

Inclusion Criteria: * End stage renal disease documented by clinical symptoms and/or laboratory findings * Patients scheduled for their first PD catheter implantation * Eligible for peritoneal dialysis (CAPD) * Willing and able to attend all study follow-up visits * Willing and able to understand and sign the informed consent form Exclusion Criteria: * A history of allergy to rifampin, trimethoprim or triclosan * Use contact lenses or have lens implants * Pregnant, lactating or planning to become pregnant during the course of the clinical investigation * Recent abdominal surgery, abdominal adhesions, infected abdominal wall, diaphragmatic tears or ileus * Respiratory insufficiency * Infection: * Active infections from successful completion of antibiotic treatment for routine bacterial infection less than 4 weeks of entry into the clinical investigation (screening) * Febrile viral infection within 4 weeks of entry into the clinical investigation (screening) * Less than 12 weeks from conclusion of therapy for systemic fungal infections to screening * Abnormal hematology parameters defined as severe anemia with hemoglobin \<8.5g/dL, white blood cell count of \<3,500/μl and a granulocyte count \<2,000/μl * Have collagen-vascular, connective tissue, or bleeding disorders * Used an investigational medicinal product, biologic or device within the last 30 days prior to enrollment